Delivery Order SPE2DB22D3102-SPE2DB24FL1DK
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Mesalamine delayed-release capsules. The $1,344.69 Firm Fixed Price Delivery Order contract has a completion date of September 18, 2024. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for providing a wide range of medical commodities...
- This federal contract award is for the delivery of 4,566,640,760 units of the pharmaceutical product Mesalamine DR 400 mg capsules in bottles of 180 units. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The award has a ceiling value of $1,130.13 and is a firm fixed-price delivery order contract with a completion date of December 9, 2024. This contract is...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,423.89 firm fixed-price delivery order is for the supply of 4,568,249,081 units of the prescription medication Mesalamine DR 400 mg capsules. The contract has an ultimate completion date of May 15, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,485.02, is a delivery order for 4567340127 - MESALAMINE DR 400 MG CAPSULE 180S. The contract has an ultimate completion date of February 24, 2025 and is a firm fixed price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,232.80 firm fixed-price delivery order covers the procurement of 4,567,343,614 units of Mesalamine DR 400 mg capsules. The contract has an ultimate completion date of February 24, 2025 and was awarded on February 21, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on November 14, 2025, for the supply of Mesalamine DR 400 mg capsules (180 count) valued at $9,632.65. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 17, 2025. The order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,143.43 firm fixed price delivery order is for the supply of 180 capsules of the medication Mesalamine DR 400 mg. The contract has an ultimate completion date of June 30, 2025 and was awarded on June 27, 2025. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) between...
- This federal contract award is for the delivery of MESALAMINE 800 MG DR TABLET 180S to the Defense Logistics Agency (DLA). The $11,379.36 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on January 10, 2025. The contract has an ultimate completion date of January 13, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery...
- This federal contract award, valued at $7,439.33, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,568,092,208 capsules of the prescription medication Mesalamine DR 400 mg, with a performance period extending through May 1, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 180 capsules of 400 mg Mesalamine DR (delayed release) with a ceiling value of $5,439.88. The contract has an ultimate completion date of May 14, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999.00, which provides a...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB24FL1DKDelivery Order
This federal contract award is for the delivery of Mesalamine DR 400 mg capsule 180s, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to the prime contractor, AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, has a ceiling value of $1,261.62, and an ultimate completion date of May 16, 2024. The contract is not associated with any set-aside requirements. In addition to this specific delivery order, AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 5/15/24 |